Epidemiology of Medication-Related Osteonecrosis of the Jaw



Osteonecrosis of the jaw is a devastating side effect of long-term bisphosphonate (BP) use. We investigated epidemiological aspects of Bisphosphonate-related osteonecrosis of the jaws (BRONJ/MRONJ).

The epidemiology of BRONJ/MRONJ was divided according to the type of BPs and the route of administration: specifically, osteoporotic patients who are often administered oral BPs and cancer patients who predominantly receive intravenous BPs.

The prevalence of BRONJ/MRONJ with oral BP use was estimated as being between 0.01 and 0.05 %, and it was higher after dental extraction. The prevalence of BRONJ/MRONJ with intravenous BP administration reached as high as 10 %, with the highest prevalence observed among multiple myeloma patients and the lowest prevalence measured among breast cancer patients.


Breast Cancer Patient Multiple Myeloma Zoledronic Acid Prostate Cancer Patient Tooth Extraction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Kanis JA, Gertz BJ, Singer F, et al. Rationale for the use of alendronate in osteoporosis. Osteoporos Int. 1995;5:1–13.PubMedCrossRefGoogle Scholar
  2. 2.
    Glover D, Lipton A, Keller A, et al. Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study. Cancer. 1994;74:2949–55.PubMedCrossRefGoogle Scholar
  3. 3.
    Body JJ, Lortholary A, Romieu G, et al. A dose-finding study of zoledronate in hypercalcemic cancer patients. J Bone Miner Res. 1999;14:1557–61.PubMedCrossRefGoogle Scholar
  4. 4.
    Rogers MJ, Watts DJ, Russell R. Overview of bisphosphonates. Cancer. 1997;80(8 Suppl):1652–60.PubMedCrossRefGoogle Scholar
  5. 5.
    Boissier S, Ferreras M, Peyruchaud O, et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res. 2000;60:2949–54.PubMedGoogle Scholar
  6. 6.
    Wang J, Goodger NM, Pogrel MA. Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg. 2003;61:1104–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61:1115–7.PubMedCrossRefGoogle Scholar
  8. 8.
    Ruggiero SL, Mehrotra B, Rosenberg TJ, et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004;62:527–34.PubMedCrossRefGoogle Scholar
  9. 9.
    Marx RE, Sawatari Y, Fortin M, et al. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005;63:1567–75.PubMedCrossRefGoogle Scholar
  10. 10.
    Migliorati CA, Casiglia J, Epstein J, et al. Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper. J Am Dent Assoc. 2005;136:1658–68.PubMedCrossRefGoogle Scholar
  11. 11.
    Mavrokokki T, Cheng A, Stein B, et al. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg. 2007;65:415–23.PubMedCrossRefGoogle Scholar
  12. 12.
    Yarom N, Yahalom R, Shoshani Y, et al. Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome. Osteoporos Int. 2007;18:1363–70.PubMedCrossRefGoogle Scholar
  13. 13.
    Lazarovici TS, Yahalom R, Taicher S, et al. Bisphosphonate-related osteonecrosis of the jaws: a single-center study of 101 patients. J Oral Maxillofac Surg. 2009;67:850–5.PubMedCrossRefGoogle Scholar
  14. 14.
    Lazarovici TS, Yahalom R, Taicher S, et al. Bisphosphonate-related osteonecrosis of the jaws associated with dental implants. J Oral Maxillofac Surg. 2010;68:790–6.PubMedCrossRefGoogle Scholar
  15. 15.
    Hellstein JW, Marek CL. Bisphosphonate osteochemonecrosis (bis-phossy jaw): is this phossy jaw of the 21st century? J Oral Maxillofac Surg. 2005;63:682–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Russell RG, Watts NB, Ebetino FH, et al. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008;19:733–59.PubMedCrossRefGoogle Scholar
  17. 17.
    Allegra A, Oteri G, Nastro E, et al. Patients with bisphosphonates-associated osteonecrosis of the jaw have reduced circulating endothelial cells. Hematol Oncol. 2007;25:164–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Landesberg R, Cozin M, Cremers S. Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg. 2008;66:839–47.PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Watts NB, Diab DL. Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab. 2010;95:1555–65.PubMedCrossRefGoogle Scholar
  20. 20.
    Population Division of the Department of Economic and Social Affairs of the United Nations Secretariat: World Population Prospects: The 2012 Revision. New York: United Nations; 2013Google Scholar
  21. 21.
    Bleibler F, Konnopka A, Benzinger P, et al. The health burden and costs of incident fractures attributable to osteoporosis from 2010 to 2050 in Germany–a demographic simulation model. Osteoporos Int. 2013;24:835–47.PubMedCrossRefGoogle Scholar
  22. 22.
    Cauley JA. Public health impact of osteoporosis. J Gerontol A Biol Sci Med Sci. 2013;68:1243–51.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Pazianas M, Miller P, Blumentals WA, et al. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther. 2007;29:1548–58.PubMedCrossRefGoogle Scholar
  24. 24.
    American Dental Association Council on Scientific Affairs. Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations. J Am Dent Assoc. 2006;137:1144–50.CrossRefGoogle Scholar
  25. 25.
    Hong JW, Nam W, Cha IH, et al. Oral bisphosphonate-related osteonecrosis of the jaw: the first report in Asia. Osteoporos Int. 2010;21:847–53.PubMedCrossRefGoogle Scholar
  26. 26.
    Malden N, Lopes V. An epidemiological study of alendronate-related osteonecrosis of the jaws. A case series from the South-East of Scotland with attention given to case definition and prevalence. J Bone Miner Metab. 2012;30:171–82.PubMedCrossRefGoogle Scholar
  27. 27.
    Lo JC, O’Ryan FS, Gordon NP, et al. Predicting Risk of Osteonecrosis of the Jaw with Oral Bisphosphonate Exposure (PROBE) Investigators: prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg. 2010;68:243–53.PubMedCrossRefGoogle Scholar
  28. 28.
    Tennis P, Rothman KJ, Bohn RL, et al. Incidence of osteonecrosis of the jaw among users of bisphosphonates with selected cancers or osteoporosis. Pharmacoepidemiol Drug Saf. 2012;21:810–7.PubMedCrossRefGoogle Scholar
  29. 29.
    Sedghizadeh PP, Stanley K, Caligiuri M, et al. Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw: an institutional inquiry. J Am Dent Assoc. 2009;140:61–6.PubMedCrossRefGoogle Scholar
  30. 30.
    Boonyapakorn T, Schirmer I, Reichart PA, et al. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol. 2008;44:857–69.PubMedCrossRefGoogle Scholar
  31. 31.
    Vahtsevanos K, Kyrgidis A, Verrou E, et al. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol. 2009;27:5356–62.PubMedCrossRefGoogle Scholar
  32. 32.
    Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol. 2005;23:8580–7.PubMedCrossRefGoogle Scholar
  33. 33.
    Dimopoulos MA, Kastritis E, Anagnostopoulos A, et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica. 2006;91:968–71.PubMedGoogle Scholar
  34. 34.
    Wang EP, Kaban LB, Strewler GJ, et al. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. J Oral Maxillofac Surg. 2007;65:1328–31.PubMedCrossRefGoogle Scholar
  35. 35.
    Hoff AO, Toth BB, Altundag K, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res. 2008;23:826–36.PubMedCrossRefGoogle Scholar
  36. 36.
    Thumbigere-Math V, Tu L, Huckabay S, et al. A retrospective study evaluating frequency and risk factors of osteonecrosis of the jaw in 576 cancer patients receiving intravenous bisphosphonates. Am J Clin Oncol. 2012;35:386–92.PubMedCrossRefGoogle Scholar
  37. 37.
    Assaf AT, Smeets R, Riecke B, et al. Incidence of bisphosphonate-related osteonecrosis of the jaw in consideration of primary diseases and concomitant therapies. Anticancer Res. 2013;33:3917–24.PubMedGoogle Scholar
  38. 38.
    Rugani P, Luschin G, Jakse N, et al. Prevalence of bisphosphonate-associated osteonecrosis of the jaw after intravenous zoledronate infusions in patients with early breast cancer. Clin Oral Investig. 2014;18:401–7.PubMedCrossRefGoogle Scholar
  39. 39.
    Walter C, Al-Nawas B, Grötz KA, et al. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol. 2008;54:1066–72.PubMedCrossRefGoogle Scholar
  40. 40.
    Walter C, Al-Nawas B, du Bois A, et al. Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients. Cancer. 2009;115:1631–7.PubMedCrossRefGoogle Scholar
  41. 41.
    Troeltzsch M, Woodlock T, Kriegelstein S, et al. Physiology and pharmacology of nonbisphosphonate drugs implicated in osteonecrosis of the jaw. J Can Dent Assoc. 2012;78:c85.PubMedGoogle Scholar
  42. 42.
    Sivolella S, Lumachi F, Stellini E, et al. Denosumab and anti-angiogenetic drug-related osteonecrosis of the jaw: an uncommon but potentially severe disease. Anticancer Res. 2013;33:1793–7.PubMedGoogle Scholar
  43. 43.
    Taylor KH, Middlefell LS, Mizen KD. Osteonecrosis of the jaws induced by anti-RANK ligand therapy. Br J Oral Maxillofac Surg. 2010;48:221–3.PubMedCrossRefGoogle Scholar
  44. 44.
    Aghaloo TL, Felsenfeld AL, Tetradis S. Osteonecrosis of the jaw in a patient on Denosumab. J Oral Maxillofac Surg. 2010;68:959–63.PubMedCentralPubMedCrossRefGoogle Scholar
  45. 45.
    Saad F, Brown JE, Van Poznak C, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol. 2012;23:1341–7.PubMedCrossRefGoogle Scholar
  46. 46.
    Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28:5132–9.PubMedCrossRefGoogle Scholar
  47. 47.
    Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377:813–22.PubMedCentralPubMedCrossRefGoogle Scholar
  48. 48.
    Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011;29:1125–32.PubMedCrossRefGoogle Scholar
  49. 49.
    Smith MR, Saad F, Coleman R, et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet. 2012;379:39–46.PubMedCentralPubMedCrossRefGoogle Scholar
  50. 50.
    Papapoulos S, Chapurlat R, Libanati C, et al. Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res. 2012;27:694–701.PubMedCentralPubMedCrossRefGoogle Scholar
  51. 51.
    Lipton A, Fizazi K, Stopeck AT, et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer. 2012;48:3082–92.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Department of Oral and Maxillofacial SurgerySheba Medical CenterShebaIsrael

Personalised recommendations